It’s rheumatology’s time for 60-day prescribing

1 minute read

Some of the most commonly prescribed medicines in rheumatology are among the latest tranche eligible for 60-day prescribing.

As of this morning, a new tranche of medicines has been added to the list of medicines eligible for 60-day prescribing.

This includes prednisolone, leflunomide, mycophenolate and tacrolimus.

The 60-day prescription program allows patients to access higher quantity scripts on the PBS for certain medicines, provided that the patients are on stable therapy.

The first tranche of 92 medicines to be included in this program, launched in September last year, meant that patients could access 60 days’ supply of sulfasalazine, allopurinol, febuxostat, alendronate and risedronate.

The latest tranche, the second of three, has added some of the most commonly prescribed medicines in rheumatology. 

Prednisolone, in the 1mg and 5mg tablet form, will now have extended quantities available for eligible patients, as will leflunomide, mycophenolate, and tacrolimus for all formulations.

Methotrexate is on the list, but given that most prescriptions are already for more than 30 days, the program has only included the 50mg vials.

The full list is available here:

The third tranche will be released in September 2024.

End of content

No more pages to load

Log In Register ×